Humanized CAR-T Therapy for Treatment of B Cell Malignancy

Inclusion Criteria: * Age≥3 at the time of consent * Survival time\>12 weeks * B cell hematological malignancies by pathological examination * Chemotherapy failure or recurrent B cell malignancy * Creatinine\< 2.5mg/dl * Glutamic-pyruvic transaminase, glutamic oxalacetic transaminase\< 3 fold of normal level * Karnofsky Performance Status\>50% at the time of screening * Bilirubin\<2.0mg/dl * Adequate pulmonary, renal, hepatic, and cardiac function * Fail in autologous or allogenic haemopoietic stem cell transplantation * Free of leukocytes removal contraindications Exclusion Criteria: * Pregnant or nursing women * Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening * Previous treatment with any gene therapy product * Abnormal vital signs * Highly allergic constitution or history of severe allergies, especially allergy to interleukin-2 * General infection or local severe infection, or other infection that is not controlled * Dysfunction in lung, heart, kidney and brain. * Severe autoimmune diseases * other symptoms that are not applicable for CAR-T